without special controls on three occasions (W.H.O. Technical Reports, 1966 . It has been widely used for the relief of postoperative pain (Kantor, Sunshine, Laska, Meisner, and Hopper, 1966) in the management of patients with malignant dis-ase (Beaver, Wallenstein, Houde, and Rogers, 1968; Frankendal and Kjellgren, 1971) , ischaemic heart (Scott and Orr, 1969) and limb pain (Taylor, 1971) , and in obstetric practice (Mitchell, 1963; Filler and Filler, 1966) . In two uncontrolled trials (Vignon, Chapuy, and Falconnet, 1969; DavidChausse and Laporte, 1970) , it was suggested that injections of pentazocine in doses ranging from 30 to 120 mg. per day were highly effective in patients with a variety of rheumatic diseases. The marketing of an oral preparation in 1969 made it possible to consider the use of pentazocine as a practical possibility in the long-term management of rheumatoid arthritis, although it was found to be only one-third as effective as the parenteral preparation on clinical assessment (Beaver, 1968) and on monitoring blood levels (Beckett, Taylor, and Kourounakis, 1970) .
In considering the use of pentazocine for the treatment of rheumatoid arthritis, it is unlikely that it would be an effective form of therapy on its own. It possesses no anti-inflammatory or antipyretic activity (Sterling Winthrop Laboratories, Unpublished observations). Fremont-Smith and Bayles (1965) showed that even large doses of pethidine were less effective than salicylates in relieving symptoms in active rheumatoid arthritis, and it is generally accepted that, if adequate analgesia is to be obtained, drugs combining peripheral anti-inflammatory, analgesic, and antipyretic effects must be employed (Winter, 1966; Drug Ther. Bull., 1966) .
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Results
Five out of the forty patients failed to complete the study. Three failed to return for assessment after the first week of therapy (two on pentazocine, one on placebo) and two after the second week (one on pentazocine and one on placebo). Only the remaining 35 patients who completed the trial are included in the analysis of results. Analysis of the treatment order groups showed them to be comparable with respect to age, sex, duration of disease, radiological stage of disease, articular index, grip strength, and severity of initial subjective pain and joint stiffness. They were also comparable with respect to concurrent analgesic antiinflammatory drug therapy (Table I) .
SUBJECTIVE PAIN
The numbers of patients showing changes in subjective pain score are summarized in Table II . Eighteen patients (51 per cent.) showed some improvement in pain score during the study, thirteen (37 per cent.) remained the same, and four (12 per cent.) became worse. Although thirteen patients had a better pain score while on placebo than pentazocine compared with four who had a better score while on pentazocine, the difference is not statistically significant (P > 0 05). Further analysis showed that the order of administration of treatment did not influence the distribution of change in pain scores.
JOINT STIFFNESS
The number of patients showing changes in joint stiffness score for each treatment period are shown in Table III : 22 patients (63 per cent.) had the same change in stiffness score with pentazocine as with placebo, twelve registering no change with either; six patients did better while on pentazocine; seven did better while on placebo. Order of treatment did not influence the distribution of change in stiffness scores.
ARTICULAR INDEX
The mean (±S.E.M.) of the articular index was 25-5 (±3 5) for patients in Group A (Pentazocine-Placebo) and 24-2 (±4-5) for patients in Group B (PlaceboPentazocine) before starting treatment. After the first week ofthe trial the means (±S.E.M.) were 27-3 (±4 4) for Group A and 21 7 (±3 8) for Group B, and after the second week 22-3 (±441) for Group A and 24-1 (±4 1) for Group B. The differences are not significant and the order of administration did not influence the distribution of change in the articular index. The SIDE-EFFECTS eighteen patients who experienced side-effects with The side-effects encountered during the course of the pentazocine, five preferred pentazocine, eight pretrial are tabulated (Table VII) . 21 patients (60 per ferred placebo, and five had no preference. In comcent.) complained of side-effects. Eighteen (51 per parison, of the eight patients who experienced sidecent.) had side-effects with pentazocine compared effects with placebo, three preferred pentazocine, four with eight (23 per cent.) with placebo. This difference preferred placebo, and one had no preference. is statistically significant (P < 0-05). Five patients (14 per cent.) had side-effects with both treatments. Discussion Therapy had to be discontinued because of the Clinical improvement on placebo tablets during the severity of side-effects in four patients (3 pentazocine, course of drug trials in rheumatoid arthritis is well 1 placebo). Thirteen patients (37 per cent.) had side-documented (Donnelly, Lloyd, and Campbell, 1967;  effects only with pentazocine, compared with three Boardman and Hart, 1967a ; Co-operating Clinics, (9 per cent.) who only had side-effects with placebo 1967) and may be partly attributable to placebo (P < 0-05). The order of administration of drugs did effects. Although such effects are usually assumed to not affect the incidence or the nature of side-effects, be of short duration, there is at least one report of the but the sex of the patients may have done so. Of all 24 effectiveness of placebo therapy over many months female patients, eighteen (75 per cent.) complained of (Traut and Passarelli, 1959) . In the present study side-effects either after pentazocine or placebo or about one-third of patients already receiving active both, compared to three of the eleven males (27 per analgesic anti-inflammatory drugs registered imcent.) (P < 0-05).
provement both in subjective assessment ofjoint pain Table VIII shows the relationship between drug and stiffness and in semi-objective assessment indices preference and side-effects. Of fourteen patients with such as the articular index and grip strength on no side-effects, one preferred pentazocine, five pre-receiving added placebo therapy. It is conceivable ferred placebo, and eight had no preference. Of the that concurrently administered effective analgesic therapy may have resulted in an enhancement of the placebo response, but it is interesting to note that the effectiveness of placebo was not related to order of administration in this trial. In some trials (e.g. Fearnley, Lackner, Meanock, and Bywaters, 1956) , drugs are shown to be 'effective' only when administered first, and it has previously been demonstrated that placebo becomes a more effective medication when administered as a second dose after an active test drug than after an ineffective one (Sunshine, Laska, Meisner, and Morgan, 1964; Batterman, 1965 Batterman, , 1966 Kantor and others, 1966; Batterman and Lower, 1968 Batterman and Grossman (1955) and well within the range of 21 to 59 per cent. for placebo responses found by Beecher (1955) in a wide survey. The patients entering our trial were selected as having severe and intractable pain. The effectiveness of placebos has been shown to increase with increased stress (Beecher, 1956) , but the ability to discriminate between placebo and active analgesic has also been shown to be greater when there is more initial pain (Hill and Turner, 1969) .
There was a significantly greater incidence of sideeffects during the pentazocine treatment. Nausea, vomiting, and constipation occurred with equal frequency during pentazocine and placebo therapy, while dizziness, light-headedness, drowsiness, and sweating, which were most frequent side-effects encountered, were confined largely to the pentazocine treatment period. Short-term trials involving small numbers of patients are not adequate for assessing the true incidence or clinical importance of side-effects, but the 51 per cent. overall incidence of side-effects in patients taking pentazocine in this study is high by any standard and certainly higher than that found in previous trials of oral pentazocine (Kantor and others, 1966; Gurtler and Steiger, 1967) in which single doses of 35 and 50 mg. were used. The overall incidence of side-effects was 8 per cent. after single oral doses of pentazocine in the only previously reported trial in which oral pentazocine, 35 and 50 mg., was given to patients with rheumatoid arthritis (Gurtler and Steiger, 1967) . Unfortunately these were only three patients among fifty with a variety of conditions and individual findings were not reported. In one trial in which oral pentazocine 50 to 100 mg. four times a day was administered to 72 patients with osteoarthrosis in general practice, the incidence and pattern of side-effects were comparable to those found in this study (General Practitioner Research Group, 1971) . Our study seems to confirm the findings of Kantor and others (1966) that side-effects with pentazocine are more frequent in females. Treadwell, Sever, Savage, and Copeman (1964) found that this was true for corticosteroid and corticotrophin sideeffects and Boardman and Hart (1967b) have shown the same for indomethacin side-effects in patients with rheumatoid arthritis.
Despite isolated reports of abuse and dependence after oral administration (Hart, 1969; Alars6n, Gelfond, and Alarq6n, 1971) , pentazocine would seem to be relatively free from the risk of addiction (W.H.O. Technical Reports, 1966 Reports, , 1969 Reports, , 1970 Chambers, Inciardi, and Stephens, 1971) . It is undoubtedly an effective major analgesic (Today's Drugs, 1970) which is useful for relieving pain after operations (Kantor and others, 1966) , in patients with cancer (Beaver and others, 1968) and after myocardial infarction (Scott and Orr, 1969) . It is likely that some patients with rheumatoid arthritis will be able to tolerate large oral doses or parenteral pentazocine and derive benefit from the addition of this drug to anti-inflammatory drug therapy when analgesia is inadequate. The results of this trial, however, indicate that the addition of a relatively small dose of oral pentazocine to the drug regimen of patients with rheumatoid arthritis who have inadequate pain relief from conventional anti-inflammatory analgesics is unlikely to be worthwhile. Similar limitations may apply to other potent centrally-acting analgesics, the value of which has never been demonstrated in patients with rheumatoid arthritis. Summary A double-blind cross-over trial is reported of oral pentazocine 25 mg. 4-hourly by day plus 50 mg. at night versus identical placebo tablets. Each was administered for 7 days to forty hospital out-patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory analgesic drugs in steady dosage with inadequate pain relief. Beneficial effects were noted in at least one-third of the patients, but there was no significant difference between pentazocine and placebo as judged by patient preference, joint pain, dosage employed in this study is unlikely to be of joint stiffness, grip strength, or mean articular index. value in the management of ambulant patients with There was a significantly higher incidence of side-this disease. effects with pentazocine than placebo. The signifi-The authors wish to acknowledge the financial support of cance of these findings in relation to the management the Arthritis and Rheumatism Council for Research in of rheumatoid arthritis is discussed and it is con-Great Britain. One of us (G.N.) was in receipt of a CIBA cluded that oral pentazocine used in the manner and Research Fellowship.
